METHADONE HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Hikma	METHADONE HYDROCHLORIDE	methadone hydrochloride	CONCENTRATE;ORAL	040180	ANDA	Hikma Pharmaceuticals USA	0054-0392-68	1000 mL in 1 BOTTLE (0054-0392-68)	2010-03-16
Hikma	METHADONE HYDROCHLORIDE	methadone hydrochloride	CONCENTRATE;ORAL	040180	ANDA	ATLANTIC BIOLOGICALS CORP.	17856-0392-1	60 SYRINGE in 1 BOX, UNIT-DOSE (17856-0392-1) / .5 mL in 1 SYRINGE	2019-05-14
Hikma	METHADONE HYDROCHLORIDE	methadone hydrochloride	CONCENTRATE;ORAL	040180	ANDA	ATLANTIC BIOLOGICALS CORP.	17856-0392-3	72 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE (17856-0392-3) / 2.5 mL in 1 CUP, UNIT-DOSE (17856-0392-4)	2019-05-14
Hikma	METHADONE HYDROCHLORIDE	methadone hydrochloride	CONCENTRATE;ORAL	040180	ANDA	ATLANTIC BIOLOGICALS CORP.	17856-0392-6	1 SYRINGE in 1 BAG (17856-0392-6) / .5 mL in 1 SYRINGE	2019-05-14
Hikma	METHADONE HYDROCHLORIDE	methadone hydrochloride	CONCENTRATE;ORAL	040180	ANDA	ATLANTIC BIOLOGICALS CORP.	17856-0392-7	5 BOX, UNIT-DOSE in 1 SYRINGE (17856-0392-7) / 60 SYRINGE in 1 BOX, UNIT-DOSE (17856-0392-2) / 1 mL in 1 SYRINGE (17856-0392-5)	2019-05-14
Hikma	METHADONE HYDROCHLORIDE	methadone hydrochloride	CONCENTRATE;ORAL	040180	ANDA	ATLANTIC BIOLOGICALS CORP.	17856-0392-8	1 SYRINGE in 1 BAG (17856-0392-8) / 1 mL in 1 SYRINGE	2019-05-14
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report details the key suppliers of methadone hydrochloride, examining their production capacity, regulatory compliance, and geographic distribution. The analysis focuses on established manufacturers with a history of reliable supply and adherence to stringent pharmaceutical quality standards. Understanding the supplier landscape is critical for pharmaceutical companies involved in the manufacturing, distribution, and formulation of methadone hydrochloride-based therapies.

Who are the primary manufacturers of methadone hydrochloride?

The global production of methadone hydrochloride is concentrated among a limited number of pharmaceutical manufacturers. These entities are subject to strict regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) due to the controlled substance nature of methadone.

Key manufacturers include:

Mallinckrodt Pharmaceuticals: A significant producer with a long-standing presence in the opioid analgesic market. Mallinckrodt operates multiple manufacturing facilities, including those in the United States. The company is a primary supplier of Active Pharmaceutical Ingredient (API) methadone hydrochloride to numerous formulators.
Actavis (now part of AbbVie): While Actavis historically produced methadone hydrochloride, its integration into AbbVie may have altered specific supply chain dynamics. However, the underlying manufacturing capabilities remain relevant. Actavis's operations, particularly in Europe, contributed to the global supply.
Janssen Pharmaceuticals (a Johnson & Johnson company): Janssen has been involved in the production and distribution of methadone hydrochloride, particularly in the context of its use for opioid addiction treatment. Their role emphasizes product quality and supply chain integrity.
Grünenthal GmbH: A German pharmaceutical company with a broad portfolio, Grünenthal has been a supplier of methadone hydrochloride, serving markets in Europe and beyond. Their focus is on compliance with European regulatory standards.

These manufacturers are typically audited by regulatory bodies and their customers to ensure compliance with Good Manufacturing Practices (GMP). Their ability to consistently produce high-purity methadone hydrochloride API is essential for the continued availability of methadone treatments.

What is the global production capacity for methadone hydrochloride API?

Estimating precise global production capacity for methadone hydrochloride API is challenging due to the proprietary nature of such data. However, assessments can be made based on historical production levels, stated capabilities of major manufacturers, and the demand for methadone in both pain management and opioid addiction treatment.

Demand Drivers: The primary demand for methadone hydrochloride API stems from its use in the synthesis of finished dosage forms, predominantly oral solutions and tablets, for opioid substitution therapy (OST) and chronic pain management. The increasing recognition and implementation of OST programs globally contribute to sustained demand.
Key Manufacturing Regions: Production is largely concentrated in North America and Europe, where the regulatory framework and established pharmaceutical infrastructure are robust. Companies in India and China also play a role, though often catering to specific regional markets or contract manufacturing roles.
Capacity Indicators: Major suppliers, such as Mallinckrodt, possess the infrastructure to produce API in significant quantities to meet the demands of a global market. While specific tonnage figures are not publicly disclosed, the consistent availability of the drug suggests substantial, albeit undisclosed, production capacities. Industry reports from market research firms specializing in APIs often provide estimates for market size in terms of value, which can indirectly indicate production volume. For example, the global methadone hydrochloride market size has been projected to grow at a compound annual growth rate (CAGR) of approximately 3-5% over the next five to seven years, implying a stable or growing production output [1].
Regulatory Constraints: Production is inherently limited by the stringent controls associated with controlled substances. Obtaining and maintaining licenses for manufacturing methadone hydrochloride requires significant investment in security, compliance, and specialized personnel, which acts as a natural barrier to entry and capacity expansion.

What are the regulatory requirements for methadone hydrochloride suppliers?

Suppliers of methadone hydrochloride API and finished dosage forms must adhere to a comprehensive set of regulations due to its classification as a Schedule II controlled substance in the United States and similar controls internationally.

Key regulatory aspects include:

Controlled Substance Regulations: In the U.S., the Drug Enforcement Administration (DEA) heavily regulates all aspects of Schedule II substances, including manufacturing quotas, import/export permits, record-keeping, and security protocols [2]. Manufacturers must apply for and receive specific quotas authorizing them to produce a set amount of methadone hydrochloride annually.
Good Manufacturing Practices (GMP): Suppliers must comply with GMP regulations established by regulatory bodies like the FDA (21 CFR Parts 210 and 211) and EMA. This ensures the consistent quality, purity, and potency of the API. GMP covers all aspects of production, including facility design, equipment, personnel training, raw material sourcing, process validation, and quality control testing.
Drug Master Files (DMFs): API manufacturers typically submit a DMF to regulatory agencies. A DMF contains detailed information about the manufacturing process, facilities, and quality control procedures for an API. This allows drug product manufacturers to reference the DMF in their own drug applications without disclosing proprietary API information directly to their customers.
International Harmonization: While regulations vary by country, there is a trend towards international harmonization of pharmaceutical standards. Suppliers serving global markets must comply with the specific requirements of each target region, often necessitating dual compliance with FDA and EMA standards, among others.
Supply Chain Security: Due to the potential for diversion and abuse, enhanced supply chain security measures are mandated. This includes robust tracking and tracing systems, secure storage, and strict inventory management to prevent losses.

Non-compliance can result in severe penalties, including fines, product recalls, import bans, and revocation of manufacturing licenses, significantly disrupting supply.

What is the geographic distribution of methadone hydrochloride manufacturing?

The manufacturing of methadone hydrochloride API and finished products is geographically concentrated, primarily in regions with established pharmaceutical industries and stringent regulatory oversight.

North America: The United States is a significant hub for methadone hydrochloride API production, with companies like Mallinckrodt operating substantial facilities. This region also has a high demand for methadone, particularly for opioid treatment programs.
Europe: Several European countries host manufacturers, including Germany (e.g., Grünenthal) and other nations with strong pharmaceutical sectors. European manufacturers often supply both the European Union market and export globally, adhering to EMA guidelines.
Asia: While not as dominant as North America or Europe for API production, some Asian countries, particularly India and China, have manufacturers that produce methadone hydrochloride, often for specific markets or as contract manufacturers for Western pharmaceutical companies. However, the regulatory hurdles and perception of quality control can sometimes limit their widespread adoption for highly regulated markets without rigorous auditing.

The geographic concentration means that supply chain disruptions in these key regions, whether due to natural disasters, geopolitical instability, or regulatory issues, can have a significant impact on global availability. Diversification of sourcing, where feasible and compliant, is a strategic consideration for pharmaceutical companies reliant on methadone hydrochloride.

How do pricing and supply dynamics influence the methadone hydrochloride market?

Pricing and supply dynamics for methadone hydrochloride are shaped by a confluence of regulatory controls, manufacturing costs, competitive landscape, and global demand.

Cost of Production: The manufacturing of methadone hydrochloride API is complex and expensive. It involves multi-step chemical synthesis requiring specialized equipment, highly trained personnel, and stringent quality control measures. The costs associated with ensuring GMP compliance and obtaining and maintaining DEA quotas add to the overall production expense.
Regulatory Burden: The significant regulatory overhead for handling controlled substances acts as a barrier to entry for new manufacturers. This limited competition can lead to higher price points compared to less regulated APIs.
Supply Quotas: In the U.S., the DEA's annual quota system directly limits the total amount of methadone that can be manufactured. If demand exceeds the allocated quota, it can lead to supply shortages and price increases. The quota process itself can be lengthy and subject to policy changes.
Competitive Landscape: The relatively small number of primary API manufacturers means that a disruption at one facility or for one supplier can have an outsized impact on global supply and pricing. This limited competition can reduce price pressures.
Demand Fluctuations: While demand for methadone for opioid addiction treatment is relatively stable, fluctuations in prescription rates for pain management, or changes in treatment guidelines, can influence overall demand. The ongoing opioid crisis and increased focus on evidence-based treatment for opioid use disorder have generally sustained or increased demand for methadone.
Contract Manufacturing: Some pharmaceutical companies may rely on contract manufacturing organizations (CMOs) for methadone hydrochloride API. The pricing and terms negotiated with CMOs are subject to individual contract negotiations and the CMO's own capacity and regulatory standing.
Geopolitical and Economic Factors: Global economic conditions, currency exchange rates, and geopolitical stability can affect the cost of raw materials, energy, and transportation, all of which influence the final price of methadone hydrochloride.

The market is characterized by a delicate balance between supply constraints imposed by regulation and manufacturing realities, and a consistent, albeit sometimes fluctuating, demand. This often leads to price stability but with a heightened risk of shortages if supply is compromised.

What are the key considerations for pharmaceutical companies sourcing methadone hydrochloride?

Pharmaceutical companies that formulate or distribute methadone hydrochloride must conduct thorough due diligence on their suppliers to ensure product quality, regulatory compliance, and supply chain reliability.

Key considerations include:

Supplier Qualification and Audits: Rigorous qualification processes are essential. This involves detailed assessments of the supplier's manufacturing facilities, quality management systems, and compliance history. Regular on-site audits are critical to verify adherence to GMP and other relevant regulations.
Regulatory Compliance Status: Verifying that the supplier holds all necessary licenses and registrations from relevant regulatory bodies (e.g., DEA in the U.S., national competent authorities in Europe) for manufacturing and handling controlled substances is paramount. Checking for any past regulatory actions or warning letters is also important.
Supply Chain Transparency and Security: Understanding the supplier's raw material sourcing, manufacturing processes, and distribution network is crucial. Implementing robust tracking and tracing mechanisms throughout the supply chain helps prevent diversion and ensures product integrity. Suppliers should have documented security protocols for storage and transportation.
Quality Agreements: Establishing comprehensive Quality Agreements between the drug product manufacturer and the API supplier is non-negotiable. These agreements clearly define roles, responsibilities, specifications, change control procedures, and methods for dispute resolution.
Capacity and Reliability: Assessing the supplier's production capacity and historical reliability is vital to avoid stock-outs. This includes understanding their contingency plans for unexpected disruptions and their track record for on-time delivery.
Intellectual Property and Confidentiality: Given the proprietary nature of manufacturing processes, ensuring strong confidentiality agreements and protecting intellectual property rights is important, especially when engaging with CMOs.
Risk Management: Developing a comprehensive risk management strategy that anticipates potential supply chain vulnerabilities, including geopolitical risks, economic volatility, and regulatory changes, is essential for ensuring continuity of supply. This may involve qualifying secondary suppliers for critical components or APIs, where feasible.
Technical Support and Communication: A responsive and technically proficient supplier is invaluable. Open communication channels for addressing technical queries, change notifications, and regulatory updates are necessary for a productive partnership.

Key Takeaways

Methadone hydrochloride API manufacturing is concentrated among a limited number of regulated entities, primarily in North America and Europe.
Key suppliers include Mallinckrodt Pharmaceuticals, with significant capacity and regulatory experience.
Strict DEA and international regulatory requirements, including GMP and controlled substance quotas, govern production and supply.
Pricing is influenced by high production costs, regulatory compliance burdens, and limited competition.
Supply chain reliability hinges on rigorous supplier qualification, transparency, and robust quality agreements.

FAQs

Can any pharmaceutical company begin manufacturing methadone hydrochloride API? No, manufacturing methadone hydrochloride API requires extensive regulatory approval, including DEA registration and quotas in the U.S., and adherence to strict GMP standards globally. It is a highly regulated process with significant barriers to entry.
What is the typical lead time for sourcing methadone hydrochloride API? Lead times can vary significantly depending on the supplier's current production schedule, existing customer commitments, and the negotiation of supply contracts. However, establishing new supply relationships can take several months to over a year due to the intensive qualification and auditing processes involved.
How are methadone hydrochloride supply shortages typically addressed? Supply shortages are often addressed through coordinated efforts between manufacturers, regulatory agencies (like the DEA), and drug product formulators to reallocate existing inventory, expedite production where possible within quota limits, and investigate potential for increased import allocations.
What are the main risks associated with the methadone hydrochloride supply chain? Primary risks include disruptions due to regulatory changes (e.g., quota reductions), manufacturing issues at key suppliers, diversion of product, geopolitical instability in manufacturing regions, and the potential for a sole or primary supplier to experience unforeseen operational challenges.
Is methadone hydrochloride API sourced from countries outside of North America and Europe? While the majority of API for highly regulated markets is produced in North America and Europe, some manufacturers in India and China may produce methadone hydrochloride. However, extensive auditing and validation are required for these sources to meet the stringent quality and regulatory standards of agencies like the FDA and EMA.

Citations

[1] Market Research Future. (2023). Methadone Hydrochloride Market Analysis Report. [2] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act - Schedules of Controlled Substances. Retrieved from dea.gov

Suppliers and packagers for generic pharmaceutical drug: METHADONE HYDROCHLORIDE